25135392|t|Anticoagulation in Patients Aged >=75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants.
25135392|a|Atrial fibrillation (AF) is an important cause of preventable, disabling stroke and is increasingly prevalent with advancing age. As life expectancies increase around the world, AF-related stroke is a growing global public health concern. Most AF patients are elderly (>=75 years old) and increasing age is a consistent independent risk factor for AF-associated stroke. Warfarin anticoagulation is highly effective for stroke prevention in AF patients, but is underutilized especially in the elderly. Although elderly patients are at increased risk of hemorrhage with oral anticoagulants, the benefit for ischemic stroke reduction exceeds the risk of hemorrhage for most elderly patients. Consequently, age alone should not be considered a contraindication for anticoagulation. Novel oral anticoagulants such as dabigatran, rivaroxaban and apixaban are at least as effective as warfarin in preventing strokes in patients with AF. Relative to warfarin, these novel agents reduce the risk of intracranial hemorrhage, the most devastating complication of anticoagulation therapy in elderly AF patients. The novel oral anticoagulants are especially appealing for stroke prevention in elderly patients with AF. 
25135392	19	27	Patients	Species	9606
25135392	49	68	Atrial Fibrillation	Disease	MESH:D001281
25135392	84	103	Oral Anticoagulants	Chemical	-
25135392	105	124	Atrial fibrillation	Disease	MESH:D001281
25135392	126	128	AF	Disease	MESH:D001281
25135392	178	184	stroke	Disease	MESH:D020521
25135392	283	285	AF	Disease	MESH:D001281
25135392	294	300	stroke	Disease	MESH:D020521
25135392	349	351	AF	Disease	MESH:D001281
25135392	352	360	patients	Species	9606
25135392	453	455	AF	Disease	MESH:D001281
25135392	467	473	stroke	Disease	MESH:D020521
25135392	475	483	Warfarin	Chemical	MESH:D014859
25135392	524	530	stroke	Disease	MESH:D020521
25135392	545	547	AF	Disease	MESH:D001281
25135392	548	556	patients	Species	9606
25135392	623	631	patients	Species	9606
25135392	657	667	hemorrhage	Disease	MESH:D006470
25135392	673	692	oral anticoagulants	Chemical	-
25135392	710	725	ischemic stroke	Disease	MESH:D002544
25135392	756	766	hemorrhage	Disease	MESH:D006470
25135392	784	792	patients	Species	9606
25135392	889	908	oral anticoagulants	Chemical	-
25135392	917	927	dabigatran	Chemical	MESH:D000069604
25135392	929	940	rivaroxaban	Chemical	MESH:D000069552
25135392	945	953	apixaban	Chemical	MESH:C522181
25135392	983	991	warfarin	Chemical	MESH:D014859
25135392	1006	1013	strokes	Disease	MESH:D020521
25135392	1017	1025	patients	Species	9606
25135392	1031	1033	AF	Disease	MESH:D001281
25135392	1047	1055	warfarin	Chemical	MESH:D014859
25135392	1095	1118	intracranial hemorrhage	Disease	MESH:D020300
25135392	1192	1194	AF	Disease	MESH:D001281
25135392	1195	1203	patients	Species	9606
25135392	1215	1234	oral anticoagulants	Chemical	-
25135392	1264	1270	stroke	Disease	MESH:D020521
25135392	1293	1301	patients	Species	9606
25135392	1307	1309	AF	Disease	MESH:D001281
25135392	Negative_Correlation	MESH:D000069552	MESH:D020521
25135392	Negative_Correlation	MESH:C522181	MESH:D001281
25135392	Cotreatment	MESH:C522181	MESH:D014859
25135392	Negative_Correlation	MESH:D000069604	MESH:D001281
25135392	Negative_Correlation	MESH:D014859	MESH:D020300
25135392	Negative_Correlation	MESH:C522181	MESH:D020521
25135392	Negative_Correlation	MESH:D000069604	MESH:D020521
25135392	Negative_Correlation	MESH:C522181	MESH:D020300
25135392	Negative_Correlation	MESH:D000069552	MESH:D020300
25135392	Negative_Correlation	MESH:D014859	MESH:D001281
25135392	Negative_Correlation	MESH:D000069552	MESH:D001281
25135392	Negative_Correlation	MESH:D014859	MESH:D020521
25135392	Negative_Correlation	MESH:D000069604	MESH:D020300
25135392	Cotreatment	MESH:D000069552	MESH:D014859
25135392	Cotreatment	MESH:D000069604	MESH:D014859

